Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of BPX-401 in patients with haematological cancer

Next Previous
Trial Profile

Phase I/II trial of BPX-401 in patients with haematological cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPX 401 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bellicum Pharmaceuticals

    • Most Recent Events

    • 12 Mar 2019 According to a Bellicum Pharmaceuticals media release, the company expects to submit an IND application for BPX-603 and to initiate a clinical trial in 2019.
    • 07 Nov 2017 According to a Bellicum Pharmaceuticals media release, the company expects to initiate this trial in the fourth quarter of 2017.
    • 09 May 2016 According to a Bellicum Pharmaceuticals media release, the company plans to initiate the clinical development of BPX-401 in the second half of 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top